- Home
- MRKR vs MBRX Comparison
MRKR vs MBRX Comparison
Compare MRKR & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- MBRX
- Stock Information
- Founded
- MRKR N/A
- MBRX 2015
- Country
- MRKR United States
- MBRX United States
- Employees
- MRKR N/A
- MBRX N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- MBRX Health Care
- Exchange
- MRKR Nasdaq
- MBRX Nasdaq
- Market Cap
- MRKR 17.7M
- MBRX 17.1M
- IPO Year
- MRKR N/A
- MBRX 2016
- Fundamental
- Price
- MRKR $1.35
- MBRX $0.67
- Analyst Decision
- MRKR Strong Buy
- MBRX Strong Buy
- Analyst Count
- MRKR 3
- MBRX 3
- Target Price
- MRKR $13.17
- MBRX $5.33
- AVG Volume (30 Days)
- MRKR 3.5M
- MBRX 10.5M
- Earning Date
- MRKR 08-13-2025
- MBRX 08-13-2025
- Dividend Yield
- MRKR N/A
- MBRX N/A
- EPS Growth
- MRKR N/A
- MBRX N/A
- EPS
- MRKR N/A
- MBRX N/A
- Revenue
- MRKR $5,696,123.00
- MBRX N/A
- Revenue This Year
- MRKR N/A
- MBRX N/A
- Revenue Next Year
- MRKR $7.16
- MBRX N/A
- P/E Ratio
- MRKR N/A
- MBRX N/A
- Revenue Growth
- MRKR 71.53
- MBRX N/A
- 52 Week Low
- MRKR $0.95
- MBRX $0.25
- 52 Week High
- MRKR $5.95
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- MRKR 40.86
- MBRX 52.44
- Support Level
- MRKR $1.41
- MBRX $0.53
- Resistance Level
- MRKR $1.61
- MBRX $0.75
- Average True Range (ATR)
- MRKR 0.31
- MBRX 0.11
- MACD
- MRKR -0.04
- MBRX 0.00
- Stochastic Oscillator
- MRKR 2.15
- MBRX 30.94
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.